A Good Peptide Site

Peptide Library

Tissue repair, musculoskeletal recovery, gastrointestinal protection

BPC-157

BPC-157 is a synthetic peptide consisting of 15 amino acids. It has historically been investigated primarily for tissue protection, wound healing, gastrointestinal effects and musculoskeletal repair.

Administration Reference

Subcutaneous

Source / Evidence Context

Human study protocol

Dose Information

200–300mcg, 500mcg for injury recovery

Frequency

Daily

Duration / Cycle

4–8 weeks general, 12 weeks for injury recovery

Off-Cycle

2-4 weeks. No clinically established schedule.

Timing

Any time

Storage Guidance

Refrigerate after reconstitution – Freeze in lyophylized powder form

Related compounds

Supplies

Affiliate disclosure: We may earn a commission if you purchase through these links.

Listings are not a required kit or confirmation of suitability for a particular peptide, formulation, or route. Check the product specifications and intended use.

Syringes & transfer supplies

  • EasyTouch U-100 Insulin Syringes (31G 0.5cc 5/16″) – 100ct.U-100 Insulin Syringes (31G 0.5cc 5/16") – 100ctInsulin syringes – Polybag, 50 Unit Capacity, 5/16” Needle Length, Bold Markings for Accurate Dosing, Disposable, Box of 100View at AMAZON →

Protective supplies & disposal

  • CURAD Isopropyl Alcohol Wipes400 Count MEDIUM SIZE PREP PADSINDIVIDUALLY WRAPPED ISOPROPYL ALCOHOL WIPES, PACK OF 4 BOXES, MEDIUM SIZE PREP PADSView at AMAZON →
  • Square Sharps Container, 2 QuartQTY 1View at AMAZON →
  • Inspire Black Nitrile Gloves HEAVY DUTY 6 Mil100ctView at AMAZON →

Browse all supplies →

Commonly Reported Uses

BPC-157 does not appear to act through one single pharmacologic target. Several mechanisms have been proposed.

Angiogenesis and VEGF signaling. Preclinical studies suggest effects on vascular endothelial growth factor signaling and formation of blood vessels involved in tissue repair.

FAK-paxillin signaling. Experimental studies suggest activation of pathways involved in cell migration, adhesion and survival—processes important during tissue repair.

Nitric oxide regulation. BPC-157 has been studied for interactions with nitric-oxide pathways affecting vascular tone, inflammation and injury response.

Inflammatory signaling. Animal studies report reductions or modulation of several inflammatory responses.

Growth-factor signaling. Alterations in signaling pathways associated with tissue growth and repair have also been observed.

The 2025 systematic review found evidence involving angiogenesis, inflammatory cytokines, cell-growth pathways and growth-hormone receptor expression. These mechanisms remain primarily preclinical findings, not established therapeutic mechanisms in humans.

Safety

Safety Considerations

Animal toxicology has generally been reassuring, but human safety data are inadequate. FDA has specifically identified potential concerns involving immunogenicity, peptide-related impurities, product characterization and the lack of sufficient human safety information.

Long-term effects, medication interactions, chronic exposure, reproductive effects and many disease-specific risks remain poorly characterized.

Angiogenesis deserves particular care. Because some experimental effects involve VEGF and vascular growth pathways, people sometimes extrapolate this into either “BPC causes cancer” or “BPC is completely safe around cancer.” Neither conclusion is supported by good human evidence. At present, it is better described as a theoretical area of concern requiring further study rather than a demonstrated carcinogenic effect.

Status

Regulatory Status

BPC-157 is not an FDA-approved drug.

FDA undertook a substantial review of BPC-157 free base and BPC-157 acetate in 2026 in connection with possible inclusion on the Section 503A bulk-drug-substances list. FDA’s scientific review concluded that the available evidence was insufficient to establish effectiveness for the evaluated ulcerative-colitis indication and raised issues involving characterization and safety.

The broader regulatory process is still distinct from drug approval. Even inclusion on a compounding list would not mean FDA had approved BPC-157 as safe and effective for tendon repair, athletic recovery or another therapeutic indication. FDA explains that 503A bulk-list decisions concern which bulk substances may qualify for specified compounding exemptions.

For athletes, the answer is considerably simpler: the 2026 WADA Prohibited List explicitly names BPC-157 under S0, meaning it is prohibited in and out of competition.

Research & Evidence

Evidence Level

Human clinical research

Research Last Reviewed

2026-08-30

Research Overview

BPC-157 has one of the broader preclinical evidence bases among commonly discussed research peptides, particularly for musculoskeletal and gastrointestinal tissue repair. However, human evidence remains extremely limited, controlled randomized trials are lacking, and commonly cited dosing protocols largely originate from experimental practice rather than validated clinical dose-finding studies.

 

Research Area Current Evidence
Tendon healing Promising animal evidence
Ligament healing Promising animal evidence
Muscle injury Promising animal evidence
Bone repair Preclinical evidence
Gastrointestinal protection Extensive preclinical literature
Inflammation Mechanistic/preclinical evidence
Vascular repair Preclinical evidence
Nerve injury Early preclinical evidence
Human musculoskeletal recovery Very limited
Long-term human use Unknown

Human Research

Knee pain

The best-known human musculoskeletal report was a retrospective case series involving patients receiving intra-articular BPC-157 for various forms of knee pain.

Among the 12 patients who received BPC-157 alone, 11 reported significant improvement in knee pain. Seven reportedly experienced improvement lasting longer than six months.

The numbers sound impressive until the study design is examined.

There was no placebo group, diagnoses were heterogeneous, follow-up wasn’t standardized, validated functional outcome measures weren’t used, and the results depended heavily on subjective patient reporting. A 2026 sports-medicine review specifically highlighted these methodological weaknesses and cautioned against broadly attributing the observed improvements to BPC-157.

Interesting signal, very weak clinical evidence.

Human safety data

A 2025 pilot study examined intravenous BPC-157 in only two adults. Participants received 10 mg and subsequently 20 mg IV infusions. Investigators reported no detectable adverse changes in the measured cardiovascular, liver, kidney, thyroid or glucose markers and no reported acute side effects.

That’s useful information, but an n=2 study cannot establish a human safety profile.

Short-term reports have not identified an obvious safety signal, but the available human population is far too small to characterize safety reliably.

References

  1. Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025;21(4):485–495. doi:10.1177/15563316251355551. PMID: 40756949.
  2. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine. 2021;27(4):8–13. PMID: 34324435.
  3. Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alternative Therapies in Health and Medicine. 2025;31(5):20–24. PMID: 40131143.
  4. Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Hatch GFR, Gamradt SC, Weber AE. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. The American Journal of Sports Medicine. 2026;54(1):223–229. doi:10.1177/03635465251357593. PMID: 41476424.
  5. U.S. Food and Drug Administration. Evaluation of BPC-157-Related Bulk Drug Substances (BPC-157 Free Base and BPC-157 Acetate) for Inclusion on the 503A Bulk Drug Substances List. FDA Briefing Document, Pharmacy Compounding Advisory Committee. May 11, 2026.
  6. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. FDA. BPC-157 entry addressing immunogenicity, peptide-related impurities, API characterization, and insufficient human safety information. Accessed September 6, 2026.
  7. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. FDA. Accessed September 6, 2026.
  8. World Anti-Doping Agency. The 2026 Prohibited List: International Standard. World Anti-Doping Code. Effective January 1, 2026. BPC-157 is listed under Section S0, Non-Approved Substances.

Featured vendor

Affiliate disclosure: We may earn a commission if you purchase through these links. A listing does not establish product safety or independent quality verification.